YM 58483 (BTP2): Selective SOCE Blocker for Fibrosis Research

Executive Summary: YM 58483 (BTP2) is a highly selective inhibitor of store-operated Ca²⁺ entry (SOCE), effectively blocking CRAC and TRP channels in non-excitable cells such as lymphocytes and fibroblasts (product information). It suppresses T cell activation by inhibiting interleukin-2 (IL-2) production with an IC₅₀ of approximately 17 nM, and potently reduces NF-AT-driven promoter activity in vitro. In vivo, BTP2 mitigates T cell-mediated immune responses and significantly reduces radiation-induced salivary gland fibrosis through the ORAI2/JNK/NFAT1 pathway (2025 study). The compound’s specificity enables precise dissection of calcium-dependent signaling in immune and fibrotic models, while its application protocols are robustly benchmarked in both cellular and animal systems.

Biological Rationale

Calcium influx via SOCE is a critical signal transduction mechanism in non-excitable cells, including T lymphocytes, macrophages, and glandular fibroblasts. The SOCE pathway is principally mediated by CRAC channels (ORAI1/ORAI2) and, to a lesser extent, by non-selective TRP channels. Dysregulated SOCE contributes to pathological conditions such as T cell-mediated autoimmunity and tissue fibrosis. Recent research highlights the importance of the ORAI2/JNK/NFAT1/TGF-β1 signaling axis in the development of early-stage postirradiation salivary gland fibrosis, establishing a direct link between aberrant calcium signaling and fibrogenesis (DOI).

Mechanism of Action of YM 58483 (BTP2), a Store-Operated Ca²⁺ Entry (SOCE) Blocker

YM 58483 (BTP2) selectively inhibits SOCE by blocking CRAC and certain TRP channels, thereby preventing sustained Ca²⁺ influx following depletion of intracellular stores. This blockade leads to suppression of Ca²⁺-dependent signaling pathways, including nuclear factor of activated T-cells (NFAT) activation and cytokine production (APExBIO). In immune cells, BTP2 reduces IL-2 secretion and inhibits T cell proliferation. In fibrogenic contexts, SOCE inhibition disrupts the ORAI2/JNK/NFAT1 axis, lowering TGF-β1 expression and myofibroblast differentiation, as demonstrated in radiation-induced gland fibrosis models (reference study). The compound's molecular weight is 421.32 g/mol (C₁₅H₉F₆N₅OS), and it is soluble in ethanol and DMSO but not in water.

Evidence & Benchmarks

• YM 58483 inhibits PHA-induced IL-2 production in T cell assays with an IC₅₀ of ~17 nM (product information).
• Pharmacologic SOCE blockade with YM 58483 reduced early-stage postirradiation fibrosis in mouse salivary glands, restoring saliva flow to 84.6% of normal levels at 30 days (DOI).
• YM 58483 suppressed the ORAI2/JNK/NFAT1/TGF-β1 pathway, markedly decreasing fibrogenesis in irradiated mouse and human submandibular gland models (DOI).
• In vivo, BTP2 significantly reduced donor anti-host cytotoxic T lymphocyte activity and interferon-γ (IFN-γ) production in mouse graft-versus-host disease models (APExBIO).
• YM 58483's effects are specific to NFAT-driven transcription, with no impact on AP-1–driven promoter activity under equivalent conditions (APExBIO).

This article extends recent work in 'YM 58483 (BTP2): Selective SOCE Blocker for Immune and Fibrosis Studies' by specifically contextualizing the impact of BTP2 on the ORAI2/JNK/NFAT1 axis in postirradiation gland models, which was not explicitly detailed in earlier discussions. It also clarifies protocol integration, supplementing guidance from 'YM 58483 (BTP2) in SOCE Blockade: Protocols and Fibrosis Models' by focusing on dosage, timing, and solution handling in fibrosis workflows.

Applications, Limits & Misconceptions

YM 58483 is widely used to dissect SOCE-mediated signaling in T cell activation, cytokine assays, and models of immune-mediated disease and fibrosis. Its high selectivity for CRAC and TRP channels makes it suitable for mechanistic studies where off-target effects must be minimized. In salivary gland fibrosis, BTP2 has demonstrated efficacy in both in vitro and in vivo settings, particularly in the context of radiation-induced injury (DOI).

However, its use is constrained by solubility limitations (insoluble in water, requiring DMSO or ethanol as solvents), and its pharmacokinetics in vivo remain incompletely characterized outside of mouse models. Misconceptions may arise regarding its applicability in excitable cells or its potential to reverse established fibrosis, which are not supported by current evidence.

Common Pitfalls or Misconceptions

• YM 58483 is not effective in excitable cells such as neurons or cardiomyocytes, where voltage-gated Ca²⁺ channels dominate.
• It does not reverse established fibrosis but prevents or mitigates early fibrogenic signaling.
• Incorrect solvent use (e.g., water) leads to precipitation and loss of activity; only DMSO or ethanol are recommended for stock solutions (APExBIO).
• The compound selectively inhibits NFAT-driven gene expression, not all Ca²⁺-dependent transcription factors.
• In vivo efficacy is well-documented in mice, but data in larger mammals or humans are lacking.

Workflow Integration & Parameters

Protocol Parameters

• Stock solution preparation: Dissolve YM 58483 at ≥90 mg/mL in DMSO or ≥50 mg/mL in ethanol; avoid water (APExBIO).
• Storage: Store solid compound and solutions at -20°C; use solutions promptly for maximal activity.
• T cell activation assay: Pre-incubate cells with YM 58483 for 30 minutes before PHA stimulation; use at concentrations yielding 10–100 nM for dose-response.
• Fibrosis modeling (in vivo): Administer YM 58483 daily by intraperitoneal injection post-irradiation for 30 days to assess effects on salivary gland fibrosis (DOI).
• Calcium imaging: Load cells with Fura-2 AM, deplete ER Ca²⁺ with thapsigargin, and assess SOCE inhibition by YM 58483 at 10–100 nM.

For advanced workflow strategies and protocol optimization, see 'YM 58483 (BTP2) in SOCE Blockade: Protocols and Fibrosis Models', which details experimental handling and troubleshooting recommendations not covered in this dossier.

Conclusion & Outlook

YM 58483 (BTP2) remains a benchmark tool for selective SOCE inhibition in immune and fibrosis research. Its unique mechanism—targeting CRAC and TRP channels—enables precise modulation of Ca²⁺-dependent pathways, particularly the ORAI2/JNK/NFAT1/TGF-β1 axis implicated in early-stage radiation-induced fibrosis. Ongoing work is focused on refining delivery, expanding in vivo validation, and exploring the translational potential in human disease models. The compound’s robust performance in preclinical studies, as distributed by APExBIO, underscores its value in dissecting the molecular underpinnings of calcium-mediated pathology (DOI).